DE19746868A1 - Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen - Google Patents

Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen

Info

Publication number: DE19746868A1
Authority: DE; Germany
Prior art keywords: tnf; treatment; interleukin; antagonists; sepsis
Prior art date: 1997-10-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

DE19746868A

Other languages

German (de)

English (en)

Inventor

Hartmut Dr Kupper

Martin Dr Kaul

Juergen Eiselstein

Lothar Dr Daum

Joachim Dr Kempeni

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Knoll GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-23

Filing date

1997-10-23

Publication date

1999-04-29

1997-10-23 Application filed by Knoll GmbH filed Critical Knoll GmbH

1997-10-23 Priority to DE19746868A priority Critical patent/DE19746868A1/de

1998-10-15 Priority to AU12284/99A priority patent/AU756167B2/en

1998-10-15 Priority to KR1020007004361A priority patent/KR20010024549A/ko

1998-10-15 Priority to PCT/EP1998/006545 priority patent/WO1999021582A2/de

1998-10-15 Priority to IL13508398A priority patent/IL135083A0/xx

1998-10-15 Priority to BR9813114-1A priority patent/BR9813114A/pt

1998-10-15 Priority to HU0100105A priority patent/HUP0100105A3/hu

1998-10-15 Priority to CNB988105144A priority patent/CN1163272C/zh

1998-10-15 Priority to CA002306790A priority patent/CA2306790A1/en

1998-10-15 Priority to EP98955459A priority patent/EP1024831A2/de

1998-10-15 Priority to JP2000517740A priority patent/JP2001521009A/ja

1998-10-22 Priority to ZA9809615A priority patent/ZA989615B/xx

1999-04-29 Publication of DE19746868A1 publication Critical patent/DE19746868A1/de

2000-04-12 Priority to NO20001894A priority patent/NO20001894L/no

Status Withdrawn legal-status Critical Current

Links

239000005557 antagonist Substances 0.000 title claims abstract description 23
102000018594 Tumour necrosis factor Human genes 0.000 title 1
108050007852 Tumour necrosis factor Proteins 0.000 title 1
102000004889 Interleukin-6 Human genes 0.000 claims abstract description 32
108090001005 Interleukin-6 Proteins 0.000 claims abstract description 32
229940100601 interleukin-6 Drugs 0.000 claims abstract description 29
210000002966 serum Anatomy 0.000 claims abstract description 19
206010040047 Sepsis Diseases 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 8
239000012634 fragment Substances 0.000 claims description 6
238000005259 measurement Methods 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 4
230000000630 rising effect Effects 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 32
102000003390 tumor necrosis factor Human genes 0.000 description 31
108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000001802 infusion Methods 0.000 description 4
102000003298 tumor necrosis factor receptor Human genes 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
229960003227 afelimomab Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000036303 septic shock Effects 0.000 description 3
230000035939 shock Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
241000272517 Anseriformes Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000020084 Bone disease Diseases 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
241000408529 Libra Species 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
239000013543 active substance Substances 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
229940124446 critical care medicine Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
229960002986 dinoprostone Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000004044 response Effects 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DE19746868A 1997-10-23 1997-10-23 Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen Withdrawn DE19746868A1 (de)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
DE19746868A DE19746868A1 (de)	1997-10-23	1997-10-23	Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
CNB988105144A CN1163272C (zh)	1997-10-23	1998-10-15	Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途
CA002306790A CA2306790A1 (en)	1997-10-23	1998-10-15	Application of tnf antagonists as medicaments for treating septic diseases
PCT/EP1998/006545 WO1999021582A2 (de)	1997-10-23	1998-10-15	Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen
IL13508398A IL135083A0 (en)	1997-10-23	1998-10-15	Application of tnf antagonists as medicaments for treating septic diseases
BR9813114-1A BR9813114A (pt)	1997-10-23	1998-10-15	Uso de antagonistas tnf para produzir medicamentos, pacote comercial, e, processo para estabelecer se um paciente que esteja sofrendo de sépsis deva ser tratado com os antagonistas tnf
HU0100105A HUP0100105A3 (en)	1997-10-23	1998-10-15	Application of tnf antagonists as medicaments for treating septic diseases
AU12284/99A AU756167B2 (en)	1997-10-23	1998-10-15	Application of TNF antagonists as medicaments for treating septic diseases
KR1020007004361A KR20010024549A (ko)	1997-10-23	1998-10-15	Ｔｎｆ 길항제의 패혈증 치료를 위한 약제로서의 용도
EP98955459A EP1024831A2 (de)	1997-10-23	1998-10-15	Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen
JP2000517740A JP2001521009A (ja)	1997-10-23	1998-10-15	敗血性疾患を治療するための医薬品としてのｔｎｆ拮抗物質の使用
ZA9809615A ZA989615B (en)	1997-10-23	1998-10-22	The use of TNF antagonists as drugs for treating septic 39disorders.
NO20001894A NO20001894L (no)	1997-10-23	2000-04-12	Anvendelse av TNF-antagonister som medikamenter for behandling av septiske sykdommer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19746868A DE19746868A1 (de)	1997-10-23	1997-10-23	Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen

Publications (1)

Publication Number	Publication Date
DE19746868A1 true DE19746868A1 (de)	1999-04-29

Family

ID=7846420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE19746868A Withdrawn DE19746868A1 (de)	1997-10-23	1997-10-23	Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen

Country Status (13)

Country	Link
EP (1)	EP1024831A2 (hu)
JP (1)	JP2001521009A (hu)
KR (1)	KR20010024549A (hu)
CN (1)	CN1163272C (hu)
AU (1)	AU756167B2 (hu)
BR (1)	BR9813114A (hu)
CA (1)	CA2306790A1 (hu)
DE (1)	DE19746868A1 (hu)
HU (1)	HUP0100105A3 (hu)
IL (1)	IL135083A0 (hu)
NO (1)	NO20001894L (hu)
WO (1)	WO1999021582A2 (hu)
ZA (1)	ZA989615B (hu)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004012766A1 (en) *	2002-08-02	2004-02-12	Goldberg, Evgeny Danilovich	Method for correcting immune responses and medicinal agent
US8637030B2 (en)	2010-07-15	2014-01-28	Oleg I. Epshtein	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2181297C2 (ru)	2000-06-20	2002-04-20	Эпштейн Олег Ильич	Способ лечения патологического синдрома и лекарственное средство
UA76639C2 (uk)	2002-08-02	2006-08-15	Олєг Ільіч Епштєйн	Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
RU2309732C1 (ru)	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2013000543A (es)	2010-07-15	2013-10-28	Oleg Iliich Epshtein	Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
ES2398646T3 (es) *	2010-07-24	2013-03-20	F. Hoffmann-La Roche Ag	Estabilización de la interleuquina-6 en soluciones de suero

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990000902A1 (en) *	1988-07-18	1990-02-08	Chiron Corporation	Monoclonal antibodies reactive with cachectin
GB9109645D0 (en) *	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
NZ278607A (en) *	1994-02-07	1999-05-28	Knoll Ag	Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

1997
- 1997-10-23 DE DE19746868A patent/DE19746868A1/de not_active Withdrawn
1998
- 1998-10-15 CA CA002306790A patent/CA2306790A1/en not_active Abandoned
- 1998-10-15 KR KR1020007004361A patent/KR20010024549A/ko not_active Ceased
- 1998-10-15 EP EP98955459A patent/EP1024831A2/de not_active Withdrawn
- 1998-10-15 WO PCT/EP1998/006545 patent/WO1999021582A2/de not_active Ceased
- 1998-10-15 JP JP2000517740A patent/JP2001521009A/ja active Pending
- 1998-10-15 HU HU0100105A patent/HUP0100105A3/hu unknown
- 1998-10-15 IL IL13508398A patent/IL135083A0/xx unknown
- 1998-10-15 BR BR9813114-1A patent/BR9813114A/pt not_active IP Right Cessation
- 1998-10-15 AU AU12284/99A patent/AU756167B2/en not_active Withdrawn - After Issue
- 1998-10-15 CN CNB988105144A patent/CN1163272C/zh not_active Expired - Fee Related
- 1998-10-22 ZA ZA9809615A patent/ZA989615B/xx unknown
2000
- 2000-04-12 NO NO20001894A patent/NO20001894L/no not_active Application Discontinuation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004012766A1 (en) *	2002-08-02	2004-02-12	Goldberg, Evgeny Danilovich	Method for correcting immune responses and medicinal agent
EA008605B1 (ru) *	2002-08-02	2007-06-29	Олег Ильич ЭПШТЕЙН	Лекарственное средство для коррекции патологических иммунных реакций
US8637030B2 (en)	2010-07-15	2014-01-28	Oleg I. Epshtein	Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract

Also Published As

Publication number	Publication date
NO20001894D0 (no)	2000-04-12
ZA989615B (en)	2000-04-20
AU756167B2 (en)	2003-01-09
CA2306790A1 (en)	1999-05-06
WO1999021582A3 (de)	1999-07-15
CN1163272C (zh)	2004-08-25
IL135083A0 (en)	2001-05-20
KR20010024549A (ko)	2001-03-26
HUP0100105A3 (en)	2003-08-28
CN1277556A (zh)	2000-12-20
EP1024831A2 (de)	2000-08-09
WO1999021582A2 (de)	1999-05-06
BR9813114A (pt)	2000-08-15
NO20001894L (no)	2000-04-12
HUP0100105A2 (hu)	2001-05-28
JP2001521009A (ja)	2001-11-06
AU1228499A (en)	1999-05-17

Publication	Publication Date	Title
EP0804236B1 (de)	2003-04-02	Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel
DE69014474T2 (de)	1995-04-20	Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DE69230862T2 (de)	2000-12-14	Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
DE60035057T2 (de)	2008-01-31	CD40 Antagonist zur Behandlung von Psoriasis
DE69925279T2 (de)	2006-01-26	Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung
DE69032662T2 (de)	1999-03-11	Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
DE112011102355T5 (de)	2013-04-25	Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
DE69629688T2 (de)	2004-06-17	Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
DE69528624T2 (de)	2003-06-26	Anti-Fas Antikörper gegen rheumatische Krankheiten
DE4307508A1 (de)	1994-09-15	Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche)
DE68908431T2 (de)	1993-12-23	Methode zur Verminderung der Immunglobulin-E-Reaktion.
DE69837322T2 (de)	2007-11-22	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE69331105T2 (de)	2002-07-11	Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen
DE3750235T2 (de)	1994-10-27	Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
EP2481757A1 (de)	2012-08-01	Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
DE19746868A1 (de)	1999-04-29	Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
DE69533311T2 (de)	2005-07-21	Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69632407T2 (de)	2005-06-02	Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
DE60312684T2 (de)	2007-12-06	Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
DE4409513C1 (de)	1995-10-19	Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
EP1235592B1 (de)	2007-11-14	Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
DE69937057T2 (de)	2008-05-29	Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
DE4408890A1 (de)	1995-09-21	Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
DE112022005300T5 (de)	2024-08-29	Zusammensetzung zur behandlung eines soliden malignen tumors und kit zur behandlung eines soliden malignen tumors
EP1171464A2 (de)	2002-01-16	Von interleukin 12 abgeleitete peptid-homodimere und peptid-heterodimere

Legal Events

Date	Code	Title	Description
2000-12-14	8139	Disposal/non-payment of the annual fee